Genetics & Genomics

Tumor Genomic Testing: Identifying Characteristics Associated With Germline Risk for Developing Malignancy

tumor genomic testing, germline genomic testing, malignancy, variant
CJON 2020, 24(6), 623-626. DOI: 10.1188/20.CJON.623-626

Tumor genomic testing is used primarily to facilitate the selection of the best possible treatment for a malignancy based on the genomic characteristics of the tumor. Germline genomic testing has implications for care and recommendations for cancer prevention and early detection for the patient and their family. Careful review of specific components of tumor genomic testing reports and of the family history of malignancy can help ensure that families with potential germline risk are identified and referred for genetic counseling and genetic testing.


  • Tumor genomic testing can provide information about what might be the best treatment for a malignancy and the potential germline risk for developing a malignancy.
  • Clinical nurse competency includes the ability to understand a tumor genomic testing report, which lists possible indicators of germline risk.
  • The identification of patients and families with potential germline risk, as well as referral of these families for genetic counseling and testing, can facilitate implementation of the best possible recommendations for cancer prevention and early detection for patients and family members.
Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.